Pacira BioSciences Newsroom

Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38

MT NewswiresJul 3 05:45 ET

Pacira BioSciences Analyst Ratings

BenzingaJul 2 13:24 ET

HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target

BenzingaJul 2 13:23 ET

HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target

BenzingaMay 8 15:26 ET

Pacira BioSciences Analyst Ratings

BenzingaMay 8 14:12 ET

Barclays Maintains Overweight on Pacira BioSciences, Lowers Price Target to $38

BenzingaMay 8 14:12 ET

Analyst Ratings For Pacira BioSciences

BenzingaMay 8 14:00 ET

Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating

MT NewswiresMay 8 10:38 ET

Pacira BioSciences Analyst Ratings

BenzingaMay 8 06:41 ET

Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $43

BenzingaMay 8 06:41 ET

Pacira BioSciences Analyst Ratings

BenzingaApr 9 06:36 ET

Teva Upgraded at J.P. Morgan on Upcoming Catalysts

Seeking AlphaMar 8 10:24 ET

Pacira BioSciences Analyst Ratings

BenzingaMar 7 05:07 ET

Pacira BioSciences Analyst Ratings

BenzingaMar 4 07:04 ET

RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating

MT NewswiresMar 1 08:08 ET

Pacira BioSciences Analyst Ratings

BenzingaMar 1 05:28 ET

Pacira BioSciences Analyst Ratings

BenzingaFeb 8 08:30 ET

RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating

MT NewswiresJan 3 08:06 ET

Raymond James Initiates Coverage On Pacira BioSciences With Outperform Rating, Announces Price Target of $42

BenzingaDec 20, 2023 06:31 ET

Pacira BioSciences Analyst Ratings

BenzingaDec 20, 2023 06:30 ET